References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.14412/1995-4484-2012-1184

rsp-1098

Research Article

Статьи

Articles

IgG4-СВЯЗАННОЕ СИСТЕМНОЕ ЗАБОЛЕВАНИЕ. СОВРЕМЕННЫЙ ВЗГЛЯД НА «СТАРЫЕ» БОЛЕЗНИ

IgG4-LINKED SYSTEMIC DISEASE. MODERN OUTLOOK ON «OLD» DISEASE

Седышев

С. Х.

Sedyshev

Samir Khasanovich

младший научный сотрудник лаб. оратории интенсивных методов терапии

mladshiy nauchnyy sotrudnik lab. oratorii intensivnykh metodov terapii

sedishev@mail.ru

Vasiliev

V I

Vasiliev

V I

ведущий научный сотрудник лаборатории интенсивных методов терапии, проф., д.м.н.

vedushchiy nauchnyy sotrudnik laboratorii intensivnykh metodov terapii, prof., d.m.n.

Kovriguina

A M

Kovriguina

A M

заведующая патологоанатомическим отделением, д.б.н.

zaveduyushchaya patologoanatomicheskim otdeleniem, d.b.n.

Насонов

Евгений Львович

Nasonov

E L

директор, акад. РАМН, д.м.н.

direktor, akad. RAMN, d.m.n.

2012

15102012

505

№5 (2012)

6472

2012

Седышев С.Х., Vasiliev V.I., Kovriguina A.M., Насонов Е.Л.

Sedyshev S.K., Vasiliev V.I., Kovriguina A.M., Nasonov E.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/1098

References1

<div>Zhang L., Smyrk T.C. Autoimmune pancreatitis and IgG4-related systemic diseases. Int J Clin Exp Pathol 2010; 3: 491-504.Aucouturier A., Danon F., Daveau M. et al. Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. J Immun Meth 1984; 74: 151-62.Meulenbroek A.J., Zeijlemaker W.P. Human IgG Subclasses: useful diagnostic markers for immunocompetence [online]. Sanquin, Laboratory for Experimental and Clinical Immunology University of Amsterdam, the Netherlands; 1996 (http://www.xs4all.nl/_ednieuw/IgGsubclasses/subkl.htm).Salfeld J.G. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25: 1369-72.Aalberse R.C., Stapel S.O., Schuurman J. et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-77.Zen Y., Fujii T., Harada K. et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45(6): 1538-46.Aalberse R.C., Platts-Mills T.A. How do we avoid developing allergy: modifications of the TH2 response from a B-cell perspective. J Allergy Clin Immunol 2004; 113: 983-6.Kawa S., Ota M., Yoshizawa K. et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002; 122: 1264-9.Scalapino K.J., Daikh D.I. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 2008; 223: 143-55.Chang M.C., Chang Y.T., Tien Y.W. et al. T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clin Chem 2007; 53: 1700-5.Umemura T., Ota M., Hamano H. et al. Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol 2008; 103: 588-94.Okazaki K., Uchida K., Ohana M. et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology 2000; 118: 573-81.Aparisi L., Farre A., Gomez-Cambronero L. et al. Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis. Gut 2005; 54: 703-9.Nishimori I., Miyaji E., Morimoto K. et al. Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis. Gut 2005; 54: 274-81.Asada M., Nishio A., Uchida K. et al. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas 2006; 33: 20-6.Löhr J.M., Faissner R., Koczan D. et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol 2010; 105: 2060-71.Yamamoto M., Naishiro Y., Suzuki C. et al. Proteomics analysis in 28 patients with systemic IgG4-related plasmacytic syndrome. Rheumatol Int 2010; 30: 565-8.Akitake R., Watanabe T., Zaima C. et al. Possible involvement of T helper type 2 responses to Toll-like receptor ligands in IgG4-related sclerosing disease. Gut 2010; 59: 542-5.Miyake K., Moriyama M., Aizawa K. et al. Peripheral CD4 T cells showing aTh2 phenotype in a patient with Mikulicz's disease associated with lymphadenopathy and pleural effusion. Mod Rheumatol 2008; 18: 86-90.Kudo-Tanaka E., Nakatsuka S., Hirano T. et al. A case of Mikulicz's disease with Th2-biased cytokine profile: possible feature discriminable from Sjö gren's syndrome. Mod Rheumatol 2009; 19: 691-5.Suzuki K., Tamaru J.I., Okuyama A. et al. IgG4-positive multiorgan lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked il 4 elevation. Rheumatology (Oxford) 2010; 49: 1789-91.Kanari H., Kagami S., Kashiwakuma D. et al. Role of Th2 cells in IgG4-related lacrimal gland enlargement. Int Arch Allergy Immunol 2010; 152(Suppl. 1): 47-53.Zen Y., Fujii T., Harada K et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45(6): 1538—46.Koyabu M., Uchida K., Miyoshi H. et al. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol 2010; 45: 732-41.Miyoshi H., Uchida K., Taniguchi T. et al. Circulating naive and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas 2008; 36: 133-40.Detlefsen S., Sipos B., Zhao J. et al. Autoimmune pancreatitis: expression and cellular source of profibrotic cytokines and their receptors. Am J Surg Pathol 2008; 32: 986-95.Kamisawa T., Anjiki H., Egawa N., Kubota N. Allergic manifestations in autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2009; 21: 1136-9.Sah R.P., Pannala R., Zhang L. et al. Eosinophilia and allergic disorders in autoimmune pancreatitis. Am J Gastroenterol 2010. doi: 10.1038/ ajg.2010.236 [Epub. ahead of print].Kojima M., Sipos B., Klapper W. et al. Autoimmune pancreatitis: frequency, IgG4 expression, and clonality of T and B cells. Am J Surg Pathol 2007; 31: 521-8.Song M.H., Kim M.H., Jang S.J. et al. Comparison of histology and extracellular matrix between autoimmune and alcoholic chronic pancreatitis. Pancreas 2005; 30: 272-8.Suda K., Nishimori I., Takase M. et al. Autoimmune pancreatitis can be classified into early and advanced stages. Pancreas 2006; 33: 345-50.Dhall D., Suriawinata A.A., Tang L.H. et al. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Human Pathol 2010; 41: 643-52.Geyer J.T., Deshpande V. IgG4-associated sialadenitis. Curr Opin Rheumatol 2011; 23: 95-101.Smyrk T.C. Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol 2011; 23(1): 74-9Masaki Y., Dong L., Kurose N. et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-5.Yoshida K., Toki F., Takeuchi T. et al. Chronic pancreatitis caused by an autoimmune abnormality: proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40: 1561-8.Montano-Loza A.J., Lalor E., Mason A.L. Recognizing immunoglobulin G4-related overlap syndromes in patients with pancreatic and hepatobiliary diseases. Can J Gastroenterol 2008; 22(10): 840-6.Chari S.T., Kloeppel G., Zhang L. et al. Histopathologic and clinical subtypes ofautoimmune pancreatitis: the Honolulu consensus document. Pancreas 2010; 39: 549-54.Okazaki K., Kawa S., Kamisawa T. et al. Japanese clinical guidelines for autoimmune pancreatitis. Pancreas 2009; 38: 849-66.Kamisawa T., Egawa N., Nakajima H. et al. Extrapancreatic lesions in autoimmune pancreatitis. J Clin Gastroenterol 2005; 39: 904-7.Kamisawa T., Funata N., Hayashi Y. et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-4.Kamisawa T., Nakajima H., Egawa N. et al. IgG4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis and retroperitoneal fibrosis with lymphadenopathy. Pancreatology 2006; 6: 132-7.Kamisawa T., Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006; 41: 613—25.Okazaki K., Kawa S., Kamisawa T. et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 2006; 41: 626—31Zamboni G., Luttges J., Capelli P. et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virch Arch 2004; 445: 552-63.Park D.H., Kim M.H., Chari S.T. Recent advances in autoimmune pancreatitis. Gut 2009; 58: 1680-9.Kamisawa T., Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008; 14: 3948-55.Chari S.T., Takahashi N., Levy M.J. et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 10: 1097-103.Okazaki K., Kawa S., Kamisawa T. et al. Japanese consensus guidelines for management of autoimmune pancreatitis. I: Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol 2010; 45: 249-65.Kamisawa T., Takuma K., Egawa N. et al. Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol 2010; 4: 401—9.Raina A., Krasinskas A.M., Greer J.B. et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132: 48-53.Ghazale A., Chari S.T., Smyrk T.C. et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102: 1646—53.Kamisawa T., Shimosegawa T., Okazaki K. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504—7.LaRusso N.F., Wiesner R.H., Ludwig J. et al. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310: 899—903.Wiesner R.H., Grambsch P.M., Dickson E.R. et al. Primary sclerosing cholangitis: natural history, prognostic factor and survival analysis. Hepatology 1989; 10: 430-6.Kamisawa T., Takuma K., Anjiki H. et al. Sclerosing cholangitis associated with autoimmune pancreatitis differs from primary sclerosing cholangitis. World J Gastroenterol 2009; 15: 2357—60.Hamano H., Kawa S., Uehara T. et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc 2005; 62: 152—7.Hayashi K., Nakazawa T., Ohara H. et al. Autoimmune sclerosing cholangiopancreatitis with little pancreatic involvements by imaging findings. Hepatogastroenterology 2007; 54: 2146-51.Nishino T., Oyama H., Hashimoto E. et al. Clinicopathological differences between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol 2007; 42: 550—9.Alderlieste Y.A., Elzen B.D.J., Rauws E.A.J. et al. Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 2009; 79: 220—8.Bjornsson E., Chari S., Sliveira M. et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther (in press).Mikulicz J. Uber eine eigenartige symmetrische erkrankung der thrä nen- und mundspeicheldrü sen. In: Billroth T., ed. Beiträ ge zur chirurgie festschrift gewidmet. Stuttgart: Ferdinand Enke, 1892; 610—30.Cимонова М.В., Васильев В.И., Корнилова Н.Н. и др. Дифференциальная диагностика болезни Микулича и болезни Шегрена. Стоматология 1988; 3: 71-3.Mikulicz J. Concerning a peculiar symmetrical disease of the lacrimal and salivary glands. Modern Classics 1937—1938; 2: 165—86.Morgan W. S., Castleman B. A clinicopathologic study of Mikulicz's disease.Am J Pathol 1953; 29: 471-503.Васильев В.И., Пальшина С.Г., Симонова М.В. и др. Первый опыт использования ритуксимаба в терапии болезни Микулича. Тер. арх. 2010; 6: 62-6.Sjögren H. Zur Kenntnis der Keratoconjunctivitis Sicca (Keratitis filiformis bei Hypofunktion der Tranendrusen). Acta Ophthalmol 1933(Suppl. II): 1—151.Morgan W.S. The probable systemic nature of Mikulicz's disease and its relation to Sjogren's syndrome. N Engl J Med 1954; 251: 5—10.MacLean H., Ironside J.W., Cullen J.F., Butt Z. Mikulicz syndrome and disease: 2 case reports high-lighting the difference. Acta Ophthalmol (Copenh) 1993; 71: 136-41.Yamamoto M., Harada S., Ohara M. et al. Clinical and pathological differences between Mikulicz's disease and Sjogren's syndrome. Rheumatology (Oxford) 2005; 44: 227-34.Yamamoto M., Takahashi H., Ohara M. et al. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol 2006; 16: 335-40Kubota K., Wada T., Kato S. et al. Highly active state of autoimmune pancreatitis with Mikulicz's disease. Pancreas 2010; 39: e6—e10.Kü ttner H. Uber entzundiche tumoren der submaaxillar-speicheldruse. Beitr Klin Chir 1896; 15: 815-34.Chan J.K. Kuttner tumor (chronic sclerosing sialadenitis) of the submandibular gland: an underrecognized entity. Adv Anat Pathol 1998; 5: 239—51.Chow T.L., Chan T.T., Choi C.Y., Lam S.H. Kuttner's tumour (chronic sclerosing sialadenitis) of the submandibular gland: a clinical perspective. Hong Kong Med J 2008; 14: 46-9.Harrison J.D., Epivatianos A., Bhatia S.N. Role of microliths in the aetiology of chronic submandibular sialadenitis: a clinicopathological investigation of 154 cases. Histopathology 1997; 31: 237—51.Rasanen O., Jokinen K., Dammert K. Sclerosing inflammation of the submandibular salivary gland (Kuttner tumour): a progressive plasmacellular ductitis. Acta Otolaryngol 1972; 74: 297—301.Isacsson G., Isberg A., Haverling M., Lundquist P.G. Salivary calculi and chronic sialoadenitis of the submandibular gland: a radiographic and histologic study. Oral Surg Oral Med Oral Pathol 1984; 58: 622-7.Tiemann M., Teymoortash A., Schrader C. et al. Chronic sclerosing sialadenitis of the submandibular gland is mainly due to a T lymphocyte immune reaction. Mod Pathol 2002; 15: 845—52.Kamisawa T., Nakajima H., Hishima T. Close correlation between chronic sclerosing sialadenitis and immunoglobulin G4. Intern Med J 2006; 36: 527-9.Takano K.I., Yamamoto M., Takahashi H. et al. Clinicopathologic similarities between Mikulicz disease and Kü ttner tumor. Am J Otolaryngol 2009 Oct 30 [Epub. ahead of print].Jacobs D., Galetta S. Diagnosis and management of orbital pseudotumour. Curr Opin Ophthalmol 2002; 13: 347-51.Mombaerts I., Goldschmeding R., Schlingemann R.O., Koornneef L. What is orbital pseudotumour? Surv Ophthalmol 1996; 41: 66—78.Rootman J., Nugent R. The classification and management of acute orbital pseudotumours. Ophthalmology 1982; 89: 1040-8.Shikishima K., Kawai K., Kitahara K. Pathological evaluation of orbital tumours in Japan: analysis of a large case series and 1379 cases reported in the Japanese literature. Clin Exp Ophthalmol 2006; 34: 239-44.Yuen S.J.A., Rubin P.A.D. Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin North Am 2002; 15: 121-6.Leone C.R. Jr, Lloyd W.C. 3rd. Treatment protocol for orbital inflammatory disease. Ophthalmology 1985; 92: 1325-31.Orcutt J.C., Garner A., Henk J.M. et al. Treatment of idiopathic inflammatory orbital pseudotumours by radiotherapy. Br J Ophthalmol 1983; 67: 570-4.Rootman J., McCarthy M., White V. et al. Idiopathic sclerosing inflammation of the orbit. A distinct clinicopathologic entity. Ophthalmology 1994; 101: 570-84.Abramovitz J.N., Kasdon D.L., Sutula F. et al. Sclerosing orbital pseudotumour. Neurosurgery 1983; 12: 463-8.Weissler M.C, Miller E., Fortune M.A. Sclerosing orbital pseudotumour: a unique clinicopathologic entity. Ann Otol Rhinol Laryngol 1989; 98: 496-501.McCarthy J.M., White V.A., Harris G. et al. Idiopathic sclerosing inflammation of the orbit: immunohistologic analysis and comparison with retroperitoneal fibrosis. Mod Pathol 1993; 6: 581-7.Swamy B.N., McCluskey P., Nemet A. Idiopathic orbital inflammatory syndrome: Clinical features and treatment outcomes. Br J Ophthalmol 2007; 91(12): 1667-70.Kamisawa T., Yoshiike M., Egawa N. et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 2005; 5: 234-8.Chari S.T., Smyrk T.C., Levy M.J. et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006; 4: 1010-6.Wakabayashi T., Kawaura Y., Satomura Y. et al. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas 2005; 30: 31-9.Kubota K., Iida H., Fujisawa T. et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc 2007; 66: 1142-51.Park D.H., Kim M.H., Chari S.T. Recent advances in autoimmune pancreatitis. Gut 2009; 58: 1680-9.Kamisawa T., Chung J.B., Irie H. et al. Japan-Korea Symposium on Autoimmune Pancreatitis (KOKURA 2007). Pancreas 2007; 35: 281-4.Ito T., Nishimori I., Inoue N. et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol 2007; 42(Suppl. 18): 50-8.Ko S.B., Mizuno N., Yatabe Y. et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology 2010; 138: 1988-96.Kamisawa T., Shimosegawa T., Okazaki K. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-7.Kamisawa T., Okazaki K., Kawa S. et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45: 471-7.Kim H.M., Chung M.J., Chung J.B. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas 2010; 39: 555-60.Pannala R., Chari S.T. Corticosteroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1438-9.Hirano K., Tada M., Isayama H. et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56: 1719-24.Church N.I., Pereira S.P., Deheragoda M.G. et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007; 102: 2417-25.Khosroshahi A., Bloch D.B., Deshpande V., Stone J.H. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthr Rheum 2010; 62: 1755-62.Pennisi A., Li X., Ling W. et al. The proteasome inhibitor, borte-zomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009; 84: 6-14.Khan M.L., Colby T.V., Viggiano R.W., Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk 2010; 10: 217-9.</div>

The authors declare that there are no conflicts of interest present.